达仁堂 (600329)

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

ASH

Tags

SSE 380 IndexSSE Corporate Governance IndexTraditional Chinese MedicineLow Price-to-Earnings RatioElderly Care ConceptPharmaceutical ManufacturingPharmaceuticals and HealthcareGuozheng Value IndexGuozheng Growth IndexGene ConceptSmall Cap ValueSmall Cap GrowthHigh-Performing StocksMargin Trading and Securities LendingHigh-Dividend StocksHigh-Dividend Yield Stocks

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 77009.44
  • Circulating A-Shares(W): 56708.94
  • Earnings Per Share(RMB): 2.8000
  • Net Assets Per Share(RMB): 11.6990
  • Operating Revenue(W RMB): 366986.13
  • Total Profit(W RMB): 252021.07
  • **Net Profit Attributable to Parent(W RMB) **: 215218.22
  • Net Profit Growth Rate(%): 167.73
  • Weighted Return on Equity(%): 25.3800
  • Operating Cash Flow Per Share(RMB): 0.7670
  • Undistributed Profit Per Share(RMB): 8.8320
  • Capital Reserve Per Share(RMB): 1.2661

2. Main Business

The main business covers:

  • Processing, wholesale & retail, and manufacturing of Chinese medicinal materials, Chinese patent medicines, Chinese herbal pieces, Western medicine preparations, and healthcare products.

3. Company Basic Information

  • Company Name: Jinyao Darentang Group Co., Ltd.
  • Listing Date: 2001-06-06
  • Industry: Pharmaceuticals & Healthcare - Traditional Chinese Medicine
  • Address: No. 17 Baidi Road, Nankai District, Tianjin
  • Website: https://www.jydrt.com.cn
  • Company Profile: The company's predecessor was Tianjin Medicinal Materials Company, established in 1955. In July 1992, approved by the Tianjin Economic System Reform Commission (1992) Document No. 27 and the Tianjin Branch of the People's Bank of China Document No. 399 (1992), Tianjin Pharmaceutical Group Co., Ltd. was established as a whole restructuring and定向募集设立 with Tianjin Pharmaceutical Group Company as the main body. The total share capital was 229,654,360 shares. In September 1995, the company underwent asset restructuring with Tianjin Pharmaceutical General Company. The company replaced 28 wholly-owned and控股 subsidiaries with poor profitability or losses with the 25% equity of Sino-American Tianjin SmithKline & French Laboratories Ltd., 30% equity of Tianjin Biefei Pharmaceutical Co., Ltd., and 80% equity of Tianjin Hualida Bioengineering Co., Ltd., all owned by the wholly-owned enterprise Tianjin Amino Acid Company under Tianjin Pharmaceutical General Company. After the restructuring,

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Hong Kong Securities Clearing Company Ltd. Northbound Funds 499.54 0.88
2 CSI 500 Exchange Traded Open-End Index Securities Investment Fund Fund 413.83 0.73
3 ChinaAMC CSI Traditional Chinese Medicine Exchange Traded Open-End Index Securities Investment Fund Fund 178.41 0.31
4 Penghua CSI Traditional Chinese Medicine Exchange Traded Open-End Index Securities Investment Fund Fund 68.07 0.12
5 Zhongou Hongli Zhixuan Hybrid型 Securities Investment Fund A Class Fund 24.15 0.04
6 Zhongou Hongli Jingxuan Hybrid型 Initiation式 Securities Investment Fund A Class Fund 6.81 0.01
7 Guolian'an CSI Pharmaceutical 100 Index Securities Investment Fund A Class Fund 5.86 0.01
8 Yinhua CSI Traditional Chinese Medicine Exchange Traded Open-End Index Securities Investment Fund Fund 5.35 0.01
9 Huatai-Pinebridge CSI Traditional Chinese Medicine Exchange Traded Open-End Index Securities Investment Fund Fund 5.16 0.01
10 Jianxin Shenzhen 100 Index Enhanced型 Securities Investment Fund Fund 1.08 0.00

5. Concept Sectors

  • Pension Concept
  • Gene Concept

Remarks

  • Data update date: 2025-11-01
  • Data source: Public Market Information